Merck Nemtabrutinib Discontinued: BELLWAVE CLL Program Ends After Safety Review
Merck ended all development of its non-covalent BTK inhibitor nemtabrutinib after a monitoring committee flagged benefit-risk concerns in Phase 3 BELLWAVE-011. The trials, the reasons and what comes next.
